Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Second quarter 2025 revenues were $15.0 million
What potential catalysts (e.g., FDA approvals, product launches) could drive the stock price in the near term?
Is there any insider trading activity or notable changes in institutional ownership following the release?
What is the cash‑flow situation and balance‑sheet strength after the reported results?
25 days ago